Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Neurol Sci ; 41(10): 2961-2965, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32383049

RESUMEN

PURPOSE: Teleconsultation is a consultation between two or more physicians about the diagnostic work-up and therapeutic strategy in the treatment of an individual case by means of modern telematics. 'Drip-and-ship' teleconsultation model consists of the transfer of patients, through telematics stroke networks, with large arteries occlusions from primary to comprehensive stroke centers equipped for endovascular therapy. We retrospectively investigated appropriateness, safety, and effectiveness of 'drip-and-ship' teleconsultation model in a rural area of Tuscany. METHODS: Outcome measures were: door-to-ship time (including door-to-needle time), ratio of number treated/total sent patients, adverse events/mortality during transfer, and mortality and modified Rankin scale at 90 days. Analysis of non-treated patients was also done. RESULTS: Seventy-eight patients were included; 16/78 patients were sent for endovascular therapy alone, and 62/78 for "drip-and-ship"; 12 patients were not treated. Door-to-ship, and door-to-needle times (mean ± SD) were 105 ± 29.8 and 62.5 ± 37.5 min, respectively. The ratio number of treated/total sent patients was 0.85. At 90 days, the global mortality rate was 21%, and 40% of patients showed favorable outcome. The main cause of non-treatment was spontaneous recanalization. CONCLUSIONS: The high value for treated/total sent patients' ratio underlines that "drip-and-ship" teleconsultation model is appropriate and effective, with a few untreated patients. The model is safe, without adverse events during transfer. Taken together, our outcomes are in line with the previous reports. "Drip-and-ship" teleconsultation model is safe and effective in rural areas, allowing good selections and rapid treatments for stroke patients, based on the transfer from the primary to the comprehensive stroke center.


Asunto(s)
Isquemia Encefálica , Consulta Remota , Accidente Cerebrovascular , Isquemia Encefálica/tratamiento farmacológico , Estudios de Factibilidad , Fibrinolíticos/uso terapéutico , Humanos , Transferencia de Pacientes , Estudios Retrospectivos , Accidente Cerebrovascular/tratamiento farmacológico , Accidente Cerebrovascular/terapia , Terapia Trombolítica , Resultado del Tratamiento
2.
Mult Scler Relat Disord ; 40: 101952, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32007656

RESUMEN

BACKGROUND: Disease modifying therapy have changed the natural evolution of multiple sclerosis (MS), with efficacy demonstrated in randomized clinical trials. Standard-of-care effectiveness is needed to complement clinical trial data and highlight outcomes in real-world practice, but comparing prospective patients with historical cohorts likely introduces biases. To address these potential biases, assigning a patient with a score that expresses his/her disease prognosis before starting a therapy may make it possible to evaluate the unbiased ability of the therapy to modify disease natural history. Thus, we aimed at analyzing the effectiveness of intramuscular interferon-ß1a (im IFN-ß1a) matching by BREMSO score (Bayesian Risk Estimate for Multiple Sclerosis at Onset) a prospective real-world cohort of treated patients with a historical cohort of untreated patients. MATERIAL AND METHODS: We observed 108 newly diagnosed, treatment naïve MS patients over 12 months of treatment with im IFN-ß1a. BREMSO score was used to assign a value to each patient, giving the real-world treated patients comparable with the Historical untreated patients, on the basis of the same risk to have unfavorable evolution. RESULTS: A significantly higher percentage of relapse-free patients is observed in IFN-ß1a treated cohort vs. Historical untreated cohort (79.6% vs. 59.3%, p < 0.01). Clinical relapses risk is reduced by 2.2 times in treated patients (p = 0.01). CONCLUSIONS: We propose a promising method to manage observational data in a relatively unbiased way, in order to analyze real-world treatment effectiveness.


Asunto(s)
Factores Inmunológicos/farmacología , Interferón beta-1a/farmacología , Esclerosis Múltiple/diagnóstico , Esclerosis Múltiple/tratamiento farmacológico , Evaluación de Resultado en la Atención de Salud/métodos , Adulto , Teorema de Bayes , Estudios de Cohortes , Femenino , Humanos , Factores Inmunológicos/administración & dosificación , Inyecciones Intramusculares , Interferón beta-1a/administración & dosificación , Masculino , Persona de Mediana Edad , Estudios Observacionales como Asunto , Pronóstico , Estudios Prospectivos , Medición de Riesgo
3.
Medicine (Baltimore) ; 97(49): e13350, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30544400

RESUMEN

RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine. PATIENT CONCERNS: Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit. DIAGNOSIS AND INTERVENTIONS: Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity). OUTCOMES: The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene. LESSONS: Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity.


Asunto(s)
Antirreumáticos/toxicidad , Metotrexato/toxicidad , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Paraparesia/inducido químicamente , Paraparesia/genética , Adulto , Antirreumáticos/administración & dosificación , Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/genética , Diagnóstico Diferencial , Femenino , Humanos , Metotrexato/administración & dosificación , Paraparesia/diagnóstico , Paraparesia/terapia , Polimorfismo Genético
4.
J Neurol Sci ; 364: 105-9, 2016 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-27084226

RESUMEN

INTRODUCTION: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. METHODS: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12months (via HADS). RESULTS: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. CONCLUSION: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect in patients with measurable anxiety or depression at baseline.


Asunto(s)
Factores Inmunológicos/uso terapéutico , Trastornos del Humor/etiología , Esclerosis Múltiple/complicaciones , Esclerosis Múltiple/tratamiento farmacológico , Resultado del Tratamiento , Adolescente , Adulto , Anciano , Femenino , Humanos , Italia , Modelos Logísticos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Escalas de Valoración Psiquiátrica , Psicometría , Adulto Joven
5.
Ann Neurol ; 53(3): 376-81, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12601705

RESUMEN

Familial hemiplegic migraine (FHM) is a rare autosomal dominant disorder characterized by episodes of transient hemiparesis followed by headache. Two chromosomal loci are associated to FHM: FHM1 on chromosome 19 and FHM2 on chromosome 1q21-23. Mutations of the alpha-1A subunit of the voltage gated calcium channel (CACNA1A) are responsible for FHM1. FHM2 critical region spans 28 cM, hence hampering the identification of the responsible gene. Here, we report the FHM2 locus refining by linkage analysis on two large Italian families affected by pure FHM. The new critical region covers a small area of 0.9Mb in 1q23 and renders feasible a positional candidate approach. By mutation analysis, we excluded the calsequestrin and two potassium channel genes mapping within the narrowed FHM2 locus.


Asunto(s)
Cromosomas Humanos Par 1/genética , Ligamiento Genético/genética , Migraña con Aura/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Mapeo Cromosómico/métodos , Femenino , Humanos , Escala de Lod , Masculino , Persona de Mediana Edad , Migraña con Aura/fisiopatología , Mutación/genética , Linaje
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA